Black Bird Biotech Updates State Registrations of MiteXstream Biopesticide and Announces Recent Onboarding of Sales V.P. and Amazon(R) Store Launch

FLOWER MOUND, TX / ACCESSWIRE / May 10, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer of plant-based MiteXstream^TM biopesticide, today reported that it has now gained registration of its MiteXstream^TM biopesticide in 43 states and in D.C. Applications have been pending since last Fall in six of the remaining states, with the application for California registration nearing completion.

BBBT also announced the recent appointment of William J. LoBell as Executive V.P. of Sales and Development, who is now directing the sales and marketing efforts for MiteXstream^TM, including working directly with BBBT's lead sales and marketing agency, Spire+.

The first of Mr. LoBell's efforts has been to coordinate the successful launch of a MiteXstream Amazon® Store, which is now open to consumers.

Mr. LoBell stated, "Once, maybe twice, in a career you have an opportunity to introduce a market-changing product like MiteXstream^TM. The chemical composition, 100% plant-based, food-grade ingredients, combined with its high efficacy as a pesticide makes MiteXstream^TM truly revolutionary. The facts are, it works, it's cost-effective and it's time is now. On top of all that, I am proud to promote a product that fosters a cleaner, safer and healthier environment."

Throughout his extensive career, Mr. LoBell has held positions in all levels of product sales and distribution operations, including as Chief Operating Officer of MSMART, a developer and purveyor of nano-technologies, Chief Executive Officer of Luminec Animal Sciences Corporation, an animal health products company, Director of E-Commerce for Petsense Inc., West Coast Director of Operations and Director of Sales Programs for Petco Animal Supply Company, West Coast Regional Operating Vice President and Officer for PETSMART, INC. and Western Region District Manager for American Stores (Jewel Supermarket, Osco Drug Stores and Sav-On Drugs Inc.)

"We have been blown away with Bill's passion and true understanding of the game-changing capacities of the product, as well as his boundless energy towards getting the job done," said Fabian Deneault, President of BBBT. "We are convinced that his energy in tandem with his experience will serve our company very well into the future."

MiteXstream^TM is also currently available at: MiteXstream.com.

For news and updates, shareholders, prospective investors and prospective business partners are encouraged to follow @BBBT_Corporate on Twitter and @BlackBirdBiotech on Instagram. Also visit BBBT's corporate website, BlackBirdBiotech.com, for additional information about the company.

About BBBT

Black Bird Biotech is positioned to exploit market segments with powerful, re-imagined biotech products. Its EPA-registered biopesticide, MiteXstream^TM, eradicates mites and similar pests, including spider mites (a lethal pest in cannabis, grapes, hops, coffee, strawberries and many other agricultural crops), and eliminates molds and mildews. MiteXstream^TM is a pesticide, but it is not a poison - it's a pesticide re-imagined. The MiteXstream^TM Edge: use through the day of harvest without concern for residual "pesticide" violations, including as it pertains to state cannabis testing. MiteXstream^TM is the foundational element of the company that carries vast potential worldwide as a highly effective, safe and extremely cost-effective replacement for many traditional "poisonous" pesticides.

Forward Looking Statements:

This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Eric Newlan
Vice President
833-223-4204
eric@newlanpllc.com
BlackBirdBiotech.com

SOURCE: Black Bird Biotech, Inc.